A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.

Inclusion Criteria: * Age range: 18 - 65 years old; * Meets the revised SLE classification criteria of the American College of Rheumatology in 1997 or the SLE diagnostic classification criteria issued by EULAR/ACR in 2019; * SELENA-SLEDAI score of at least 8 points (clinical symptoms of no less than 6 points, excluding positive anti-double-stranded DNA (anti-dsDNA) and low complement); * Patients who have been using tofacitinib or belimumab for at least 12 weeks. Exclusion Criteria: * Having active central nervous system diseases; * eGFR \< 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation; * Pregnant women, or women planning to get pregnant in the near future while taking the medication, or lactating women; * Participants who are simultaneously participating in other clinical studies; * Patients who have received treatment with tixagrel or belimumab for less than 12 weeks.